TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 660-672

  Kulasekararaj, Austin G ^a,b   Smith, Alexander E ^a,b   Mian, Syed A ^a   Mohamedali, Azim M ^b   Krishnamurthy, Pramila ^a,b   Lea, Nicholas C ^b   Gäken, Joop ^a   Pennaneach, Coralie ^b   Ireland, Robin ^b   Czepulkowski, Barbara ^b   Pomplun, Sabine ^b   Marsh, Judith C ^a,b   Mufti, Ghulam J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

5 azacitidine; Chromosome 5; Myelodysplastic syndrome; TP53

Indexed keywords

AZACITIDINE; LENALIDOMIDE; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CELL COUNT; CHROMOSOME 5; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, MACROCYTIC; ANTIMETABOLITES; AZACITIDINE; BONE MARROW CELLS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873995626     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12203     Document Type: Article

References (34)

1. Allred, D.C., Clark, G.M., Elledge, R., Fuqua, S.A., Brown, R.W., Chamness, G.C., Osborne, C.K. & McGuire, W.L. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Journal of the National Cancer Institute, 85, 200-206.
2. Allred, D.C., Harvey, J.M., Berardo, M. & Clark, G.M. (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology, 11, 155-168.
3. Bejar, R. & Ebert, B.L. (2010) The genetic basis of myelodysplastic syndromes. Hematology/oncology Clinics of North America, 24, 295-315.
4. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine, 364, 2496-2506.
5. Bowen, D., Groves, M.J., Burnett, A.K., Patel, Y., Allen, C., Green, C., Gale, R.E., Hills, R. & Linch, D.C. (2009) TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia, 23, 203-206.
6. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
7. Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology, 19, 1405-1413.
8. Dutt, S., Narla, A., Lin, K., Mullally, A., Abayasekara, N., Megerdichian, C., Wilson, F.H., Currie, T., Khanna-Gupta, A., Berliner, N., Kutok, J.L. & Ebert, B.L. (2011) Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood, 117, 2567-2576.
9. Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, F.M., Reiter, A., Hochhaus, A., Drexler, H.G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F.H. & Cross, N.C. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics, 42, 722-726.
10. Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology, 25, 799-804.
11. Hurt, E.M., Thomas, S.B., Peng, B. & Farrar, W.L. (2006) Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biology & Therapy, 5, 1154-1160.
12. Iafrate, A.J., Feuk, L., Rivera, M.N., Listewnik, M.L., Donahoe, P.K., Qi, Y., Scherer, S.W. & Lee, C. (2004) Detection of large-scale variation in the human genome. Nature Genetics, 36, 949-951.
13. Jadersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Gohring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellstrom-Lindberg, E. & Mufti, G.J. (2011) TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of Clinical Oncology, 29, 1971-1979.
14. Jasek, M., Gondek, L.P., Bejanyan, N., Tiu, R., Huh, J., Theil, K.S., O'Keefe, C., McDevitt, M.A. & Maciejewski, J.P. (2010) TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia, 24, 216-219.
15. Jonveaux, P., Fenaux, P., Quiquandon, I., Pignon, J.M., Lai, J.L., Loucheux-Lefebvre, M.H., Goossens, M., Bauters, F. & Berger, R. (1991) Mutations in the p53 gene in myelodysplastic syndromes. Oncogene, 6, 2243-2247.
16. Kaneko, H., Misawa, S., Horiike, S., Nakai, H. & Kashima, K. (1995) TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood, 85, 2189-2193.
17. Kita-Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H. & Taniwaki, M. (2001) International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. British Journal of Haematology, 115, 309-312.
18. Kordasti, S., Marsh, J., Al-Khan, S., Jiang, J., Smith, A., Mohamedali, A., Abellan, P.P., Veen, C., Costantini, B., Kulasekararaj, A.G., Benson-Quarm, N., Seidl, T., Mian, S.A., Farzaneh, F. & Mufti, G.J. (2012) Functional characterization of CD4+ T cells in aplastic anemia. Blood, 119, 2033-2043.
19. Lai, J.L., Preudhomme, C., Zandecki, M., Flactif, M., Vanrumbeke, M., Lepelley, P., Wattel, E. & Fenaux, P. (1995) Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia, 9, 370-381.
20. Ludwig, L., Schulz, A.S., Janssen, J.W., Grunewald, K. & Bartram, C.R. (1992) P53 mutations in myelodysplastic syndromes. Leukemia, 6, 1302-1304.
21. el-Mahdani, N., Vaillant, J.C., Guiguet, M., Prevot, S., Bertrand, V., Bernard, C., Parc, R., Bereziat, G. & Hermelin, B. (1997) Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. British Journal of Cancer, 75, 528-536.
22. Mailman, M.D., Feolo, M., Jin, Y., Kimura, M., Tryka, K., Bagoutdinov, R., Hao, L., Kiang, A., Paschall, J., Phan, L., Popova, N., Pretel, S., Ziyabari, L., Lee, M., Shao, Y., Wang, Z.Y., Sirotkin, K., Ward, M., Kholodov, M., Zbicz, K., Beck, J., Kimelman, M., Shevelev, S., Preuss, D., Yaschenko, E., Graeff, A., Ostell, J. & Sherry, S.T. (2007) The NCBI dbGaP database of genotypes and phenotypes. Nature Genetics, 39, 1181-1186.
23. Malcovati, L., Papaemmanuil, E., Bowen, D.T., Boultwood, J., Della Porta, M.G., Pascutto, C., Travaglino, E., Groves, M.J., Godfrey, A.L., Ambaglio, I., Galli, A., Da Via, M.C., Conte, S., Tauro, S., Keenan, N., Hyslop, A., Hinton, J., Mudie, L.J., Wainscoat, J.S., Futreal, P.A., Stratton, M.R., Campbell, P.J., Hellstrom-Lindberg, E. & Cazzola, M. (2011) Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 118, 6239-6246.
24. Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., Fulton, L.A., Locke, D.P., Magrini, V.J., Abbott, R.M., Vickery, T.L., Reed, J.S., Robinson, J.S., Wylie, T., Smith, S.M., Carmichael, L., Eldred, J.M., Harris, C.C., Walker, J., Peck, J.B., Du, F., Dukes, A.F., Sanderson, G.E., Brummett, A.M., Clark, E., McMichael, J.F., Meyer, R.J., Schindler, J.K., Pohl, C.S., Wallis, J.W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M.E., Ivy, J.V., Kalicki, J., Elliott, G., Ries, R.E., Payton, J.E., Westervelt, P., Tomasson, M.H., Watson, M.A., Baty, J., Heath, S., Shannon, W.D., Nagarajan, R., Link, D.C., Walter, M.J., Graubert, T.A., DiPersio, J.F., Wilson, R.K. & Ley, T.J. (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. New England Journal of Medicine, 361, 1058-1066.
25. Padua, R.A., Guinn, B.A., Al-Sabah, A.I., Smith, M., Taylor, C., Pettersson, T., Ridge, S., Carter, G., White, D., Oscier, D., Chevret, S. & West, R. (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia, 12, 887-892.
26. Patnaik, M.M., Hanson, C.A., Hodnefield, J.M., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients. Leukemia, 26, 101-105.
27. Rucker, F.G., Schlenk, R.F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.M., Holzmann, K., Gaidzik, V.I., Paschka, P., Held, G., von Lilienfeld-Toal, M., Lubbert, M., Frohling, S., Zenz, T., Krauter, J., Schlegelberger, B., Ganser, A., Lichter, P., Dohner, K. & Dohner, H. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 2114-2121.
28. Smith, A.E., Mohamedali, A.M., Kulasekararaj, A., Lim, Z., Gaken, J., Lea, N.C., Przychodzen, B., Mian, S.A., Nasser, E.E., Shooter, C., Westwood, N.B., Strupp, C., Gattermann, N., Maciejewski, J.P., Germing, U. & Mufti, G.J. (2010) Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 116, 3923-3932.
29. Tavassoli, M., Steingrimsdottir, H., Pierce, E., Jiang, X., Alagoz, M., Farzaneh, F. & Campbell, I.G. (1996) Loss of heterozygosity on chromosome 5q in ovarian cancer is frequently accompanied by TP53 mutation and identifies a tumour suppressor gene locus at 5q13.1-21. British Journal of Cancer, 74, 115-119.
30. Walter, M.J., Graubert, T.A., Dipersio, J.F., Mardis, E.R., Wilson, R.K. & Ley, T.J. (2009) Next-generation sequencing of cancer genomes: back to the future. Personalized Medicine, 6, 653.
31. Walter, M.J., Ding, L., Shen, D., Shao, J., Grillot, M., McLellan, M., Fulton, R., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Kandoth, C., Baty, J., Westervelt, P., DiPersio, J.F., Mardis, E.R., Wilson, R.K., Ley, T.J. & Graubert, T.A. (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia, 25, 1153-1158.
32. Walter, M.J., Shen, D., Ding, L., Shao, J., Koboldt, D.C., Chen, K., Larson, D.E., McLellan, M.D., Dooling, D., Abbott, R., Fulton, R., Magrini, V., Schmidt, H., Kalicki-Veizer, J., O'Laughlin, M., Fan, X., Grillot, M., Witowski, S., Heath, S., Frater, J.L., Eades, W., Tomasson, M., Westervelt, P., DiPersio, J.F., Link, D.C., Mardis, E.R., Ley, T.J., Wilson, R.K. & Graubert, T.A. (2012) Clonal architecture of secondary acute myeloid leukemia. New England Journal of Medicine, 366, 1090-1098.
33. Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994) p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84, 3148-3157.
34. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64-69.